The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF .alpha. signaling pathway. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as "TRAF2 truncated" or "TRAF2TR" and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as "TRAF2 truncated-deleted" or "TRAF2TD". Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF .alpha. signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF .alpha. binding.

 
Web www.patentalert.com

< Molecular characteristics of non-small cell lung cancer

> Lepidopteran-active Bacillus thuringiensis .delta.-endotoxin polynucleotides, compositions, and methods of use

~ 00411